Matrix-remodeling associated 5 as a novel tissue biomarker predicts poor prognosis in non-small cell lung cancers.
Matrix-remodeling associated 5 (MXRA5) has recently been one of the frequently mutated gene but its role in non-small cell lung cancer (NSCLC) remains unclear. To identify whether MXRA5 could be applied as a novel prognostic marker for NSCLC. In this study, we proved that mRNA and protein expression of MXRA5 in 166 NSCLC patients' tissues by Quantitative Real-Time PCR and immunohistochemical staining respectively. Moreover, the correlation between MXRA5 protein expression and clinicopathological features and prognosis in NSCLC patients was evaluated. Our results revealed that the over-expression of MXRA5 was significantly correlated with age (P = 0.049), differentiation (P = 0.003), tumor-node-metastasis (TNM) stage (P = 0.017) and smoking cigarette (P = 0.007). In addition, it also showed that patients with higher MXRA5 protein expression had significantly shorter overall survival (P < 0.001). Multivariate analysis indicated that over-expression of MXRA5 protein was an independent prognostic factor for NSCLC. MXRA5 protein is aberrantly expressed in NSCLC and the high MXRA5 expression is correlated with tumor progression and overall survival. These results indicated the potential value of MXRA5 as a novel therapeutic target for the treatment of NSCLC.